Mr. Sinha received his Bachelors of Science (BS) and Master of Science (MS) degrees in Bacteriology / Natural Science from the University of Wisconsin – Madison, Wisconsin, USA. He completed his Master’s in Business Administration (MBA) from the New York Institute of Technology, New York, USA. Kuntal Sinha has been in the Pharmaceutical industry for over 25 years. His experience over the years have spanned within the Contract Research Organization (CRO) and pharmaceutical companies. At Covance, Mr. Sinha’s responsibility included research supporting Metabolic Chemistry and Drug Metabolism Since 2016, Mr. Sinha has been managing the activities associated with pharmacovigilance and clinical trial safety and serves as an advisory / consultative capacity in compliance related safety matters. More recently, Mr. Sinha is Director at Alkermes within Clinical Quality Assurance group supporting pharmacovigilance, Medical Affairs and Commercial Organization on drug safety related to adverse events and product complaints.

Clinical Trails

Physician with more than 20 years of experience in clinical development and pharmacovigilance. After working for several years as Vice President and Global Head of drug safety & risk management for Lupin, she founded Clinexel Life Sciences Pvt Limited, that provides consulting and operations services to pharma companies. Deepa has rich experience in conceptualizing innovative products, developing efficient 505b(2) clinic- regulatory strategies for biosimilar and hybrid applications. She was a key member for clinical development and safety monitoring of biosimilars & NCEs in 3 companies. She participated in regulatory meetings with FDA, EMA, rapporteurs and CHMP to discuss the clinical development plans, risk management plans, post marketing data collection required for hybrid applications and requirements of post marketing studies. She has successfully led a consortium of leading generic companies including Teva, Lupin, Sandoz, Alvogen, Mylan, Generis and Gedeon Richter in Europe to conduct post authorization clinical studies imposed as a condition of marketing authorization for a generic product. After successfully completing these studies, results were published in peer reviewed journals.

Pharmacovigilance

M.D., Medical Doctor/ Physician, graduated from Tehran university, School of Medicine with honor. He studied in neurosurgery ward and graduated with a score with thesis on Meningioma Brain Tumour during 6 years. With continuing my practice with special consideration on psychosomatic disorders, He completed many post graduate courses on health psychology, addiction medicine, sexual disorders therapy successfully. He passed many post graduate courses in Neuro, approved by Medical Sciences University. As well, He have been passed post graduate courses on Nutrition, Gastroenterology and herpetology, Obesity treatment and diabetes approved by Tehran University of Medical sciences. He is director of fatty liver and related metabolic disorders study among Iranian families since 2015 and currently publishing the results of our study and research about fatty liver and hyperlipidaemia, diabetes and nutrition as study director and clinician associate member of Iran Hepatitis Network. I am reviewer and associate editor of Hepatitis Monthly Journal and reviewer of journal of Clinical and Translational Herpetology. He is editorial board member of International Journal of Psychology and Neurosciences. He certified graduate, verified reviewer and certified mentor of Publons academy in the field of Clinical Medicine and Herpetology.

Published article in Metabolic disease pharmacology high indexed journal

He is currently working as deputy director for Institute of Regenerative Medicine and Biotherapy (IRMB) composed of a 150 persons. He is also a leader of a INSERM research team and Director of a stem cell facility CHU (SAFE-iPSC) comprising more than 33 persons. He is mentoring 8 senior scientists (CR1, MCU, MCU/PH), 11 Ph.D. students and 3 Post-Docs, 9 technicians and engineers. Also he is an invited speaker in 48 national and international conferences and seminars in France and abroad in the last 5 years (3 plenary lectures).

To explore epigenetic mechanisms involved in senescence/aging impairing stem cell renewal and reprogramming, which is of major importance aging with outcomes in regenerative medicine and cell therapies.

Nader G. Abraham is working as professor in Newyork Medical College, Newyork

Pharmacology

Essam Abdel-Sattar is currently working as professor in Cairo University, Egypt

Quality control of drugs

Dr. Yukio Yoneda is a Professor Emeritus in Kanazawa University, where he worked as a Chairman Professor of Pharmacology from 1999 to 2015. He graduated from Osaka University, Faculty of Pharmaceutical Sciences in 1972, followed by appointments in Kyoto Prefectural University of Medicine, City of Hope Research Institute, CA, USA and Setsunan University. He is serving as an Associate Editor in several international journals such as Neurochemistry International, Neurochemical Research and Journal of Neuroscience Research, in addition to acting on the Editorial Board in other international scientific journals. His research interests have been lying on pharmacological profiling of amino acid signaling in neuronal and non-neuronal cells using molecular biological techniques. As a return of laboratory experimental results to the community, he is now attempting to develop several dietary supplements beneficial for the prophylaxis of different diseases besides the bench work with colleagues in domestic and foreign universities.

Molecular pharmacology of amino acid signaling in neuronal and non-neuronal cells

She is currently working as Vice Dean for Academics, Student Affairs, and Cooperation, Postgraduate School, Universitas Padjadjaran, Indonesia. Also she is a professor in the Department of Pharmacology and Clinical Pharmacy in the same university.She is the editor/reviewer of many journals and she has won many awards.

Pharmacology

Stefan Glück, MD, PhD is a Medical Oncologist with focus on solid tumors including brain cancer activities worldwide. Additionally, he is responsible for Immuno-Oncology programs in solid tumors and hematologic diseases and is in the area of Early Assets. He completed his medical studies at the University of West Berlin, Germany in 1978 followed by a medical oncology & bone marrow transplant fellowship in Toronto, Canada. Before becoming V.P. of Global Medical Affairs at Celgene Corp., he previously served as Sylvester Professor of Medicine at the Miller School of Medicine in Miami, Florida until 2014. From 2009-2010 he was Assistant Director of the Sylvester Comprehensive Cancer Center & Associate Chief, for the Division of Hematology & Medical Oncology and from 2003-2008 he served as Clinical Director of the Braman Family Breast Cancer Institute in Miami, Florida. He has authored and co-authored over 260 articles, and has written more than 350 papers at national and international meetings.

Medical Oncology

Karen Mulkijanyan is the Head of the Department of Pharmacology at Tbilisi State Medical University Institute of Pharmacochemistry and Adviser on Technology Commercialization to aforesaid Institute’s Administration. He obtained his MS in Biochemistry in 1981 and PhD in Pharmacy in 2005. Dr. Mulkijanyan’s research interests include studying the pharmacology of anti-inflammatory and wound healing drugs and analysis and prediction of structure-activity relationship of natural, modified and synthesized compounds. He is the author and co-author of more than 90 papers in peer-reviewed journals, about 30 presentations at international scientific meetings, and 2 patents.

Pharmacology of antiinflammatory, wound healing and microcirculatory drugs. Pharmacokinetics. Toxicology. Analysis and prediction of structure-activity relationship of natural, modified and synthesized compounds.

Joseph L Borowitz is Professor Emeritus of Pharmacology in Pudue University. He had done his B.S. from Ohio State University, M.S. from Purdue University and PhD from Northwestern University. His research focuses on Neurotoxicology. Had had published many representative articles in reputed journals.

Neurotoxicology

Connie Medlen obtained a BSc (agric) in Microbiology in 1964, an MSc in 1982 and a Ph.D in Immunology in 1986 (at the age of 43). Up till now she has been employed by the University of Pretoria for 43 years after which she retired. Twenty nine MSc and nine PhD completed their studies under her supervision. After 4 years of retirement she returned to the University of Pretoria, Faculty of Medical Sciences as Research Mentor. She has published 128 research papers in ISI accredited international journals and presented at 44 International Conferences.

Natural products (including plants and herbs), Development of anti-cancer agents

Kjell Fuxe has worked at the Karolinska Institutet since 1960, became prosektor in 1968 and professor in 1979. Since 2005 Fuxe is a professor emeritus at the Department of Neuroscience. He published over 1589 papers.He is a member Royal Swedish Academy of Sciences and foreign member of the Mexican Academy of Sciences and was a member of the Nobel Assembly. He is mainly known for his work on central monoamine neurons, volume transmission and its different forms, receptor-receptor interactions in the CNS and neuropsychopharmacology.

He is mainly known for his work on central monoamine neurons, volume transmission and its different forms, receptor-receptor interactions in the CNS and neuropsychopharmacology.